Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 1,198 Shares

Key Points

• CFO Michael Burkes Brophy sold 1,198 Natera shares for approximately $510,755 at an average price of $426.34. The Rule 10b5-1 transaction was intended to cover tax withholding on vested equity awards, reducing his holdings by 2.36% to 49,658 shares.
• Natera shares rose to $436, near their 52-week high of $437.41, while the company’s latest quarterly revenue increased 37.7% year over year to $752.75 million and exceeded estimates; however, earnings remained negative at $0.47 per share.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and average price target of $394.31, though some analysts cite valuation concerns and potential volatility ahead of the company’s November 5 third-quarter results.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Brophy sold 1,198 shares of the business's stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total value of $510,755.32. Following the completion of the sale, the chief financial officer owned 49,658 shares of the company's stock, valued at approximately $21,171,191.72. This trade represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Stock Performance

NASDAQ:NTRA traded up $11.58 during midday trading on Thursday, reaching $436.00. The stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The firm's fifty day simple moving average is $375.27 and its 200-day simple moving average is $265.54.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the business earned ($0.74) EPS. The business's revenue was up 37.7% on a year-over-year basis. On average, sell-side analysts anticipate that Natera, Inc. will post -1.14 EPS for the current year.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Robert W. Baird set a $348.00 target price on Natera in a report on Friday, August 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Natera in a research note on Thursday, October 15th. Guggenheim raised their price target on shares of Natera from $360.00 to $475.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Morgan Stanley increased their target price on shares of Natera from $355.00 to $435.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. Finally, Stephens lifted their target price on Natera from $305.00 to $350.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $394.31.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently made changes to their positions in NTRA. BlackRock Inc. bought a new position in Natera during the second quarter worth about $2,962,770,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company's stock valued at $238,334,000 after purchasing an additional 11,793 shares during the period. Maverick Capital Ltd. grew its stake in shares of Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company's stock valued at $234,315,000 after purchasing an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company's stock worth $226,220,000 after buying an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Natera in the 2nd quarter worth approximately $199,960,000. Institutional investors and hedge funds own 99.90% of the company's stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.